Kite Reports Submission of sBLA to the US FDA for Tecartus in Adult Patients with R/R Acute Lymphoblastic Leukemia

 Kite Reports Submission of sBLA to the US FDA for Tecartus in Adult Patients with R/R Acute Lymphoblastic Leukemia

Kite Reports Submission of sBLA to the US FDA for Tecartus in Adult Patients with R/R Acute Lymphoblastic Leukemia

Shots:

  • The sBLA is based on data from the P- I/II ZUMA-3 trial in adult patients age ≥18 years old for the treatment of adult patients with r/r B-cell ALL
  • The focus of the study is to evaluate the safety and efficacy in adult patients with r/r ALL
  • If approved, Tecartus will be the 1st and only CAR T-cell therapy approved for adult patients. In July 2020, Tecartus received an accelerated approval from the US FDA for the treatment of r/r mantle cell lymphoma, based on ORR and DOR

Click here to­ read full press release/ article | Ref: BusinessWire | Image: BusinessWire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post